Aclarion, Inc.

Aclarion, Inc. is a U.S.-based medical technology and services company whose core offering is Nociscan, a report delivered to medical professionals to help evaluate spinal pain. The company monetizes its service by generating and delivering these reports, rather than by selling a traditional physical product. Its recent filings indicate that substantially all revenue comes from the United States and the United Kingdom, with UK growth improving after local coverage decisions. Aclarion is still in an early commercialization and funding phase, relying on equity and debt financings to support operations while it expands payer coverage and scan volumes.

−9 012,3 %

9,0 %

−9 551,9 %

+65,6 %

14.81

14.81

— Aclarion, Inc.
%
Nociscan reports100% Diagnostic reports delivered to medical professionals for spinal pain assessment and related clinical decision support.
Clinical and commercial support0% Field support, partner coordination, and commercialization activities that help drive report adoption and utilization.

Aclarion sells primarily to medical professionals and healthcare providers that order or use Nociscan reports in the...

  • Medical professionalsprimary

    Physicians and other clinicians who order Nociscan reports to support diagnosis and treatment decisions for spinal pain.

  • Healthcare providersprimary

    Hospitals, clinics, and care networks that use the service in patient workflows and need reimbursement-supported adoption.

  • UK payor-supported userssecondary

    Customers in the United Kingdom whose utilization has increased following local coverage decisions and broader payer access.

  • U.S. reimbursed userssecondary

    U.S. customers that buy the service where contract terms and reimbursement support the use of Nociscan reports.

Aclarion states that substantially all of its revenue is generated from contracts with customers in the United States...

  • •Substantially all revenue comes from the United States and United Kingdom
  • •UK growth has been driven by local coverage decisions
  • •U.S. is the home market and likely the main operating base
  • •Market access and reimbursement vary materially by country
  • •Geographic mix affects utilization, pricing, and adoption speed

Aclarion’s near-term strategy is to expand scan volumes and increase the number of insurance payors that cover or...

01
Expand payer coverage in the UKshort-term

Coverage decisions directly affect whether clinicians can order Nociscan reports at scale.

02
Increase scan volumesshort-term

Higher utilization is the main driver of revenue growth in a single-service model.

03
Preserve liquidity and secure fundingshort-term

The company has ongoing operating losses and depends on external capital to fund commercialization.

Aclarion faces execution risk because its business depends on a single revenue source, Nociscan report delivery, so any...

high

Dependence on a single service line

Revenue comes from one source, so the company lacks diversification if adoption slows or a competing approach gains traction.

Scope
Nociscan report delivery
Materiality
high
high

Reimbursement and coverage dependence

Revenue growth in the UK was driven by local coverage decisions, showing that payer access is a primary demand driver.

Scope
United Kingdom and United States healthcare payors
Materiality
high
high

Liquidity and financing risk

The company has funded operations through equity and debt offerings and expects to need capital to continue commercialization.

Scope
Operating cash burn and capital markets access
Materiality
high
medium

Market adoption risk

The business depends on clinicians ordering reports at increasing volumes, which can be slow in healthcare workflows.

Scope
Physician and provider adoption
Materiality
medium
Revenue recognition for Nociscan reports
Can shift revenue between quarters depending on volume and contract timing
Equity-based compensation valuation
Affects operating expenses and dilution
Use of estimates and assumptions
Can affect accruals, expenses, and balance sheet values

Aclaris Therapeutics, Inc.

ACRS · Pharmaceutical Preparations

ALLURION TECHNOLOGIES, INC.

ALUR · Surgical & Medical Instruments & Apparatus

Acrivon Therapeutics, Inc.

ACRV · Pharmaceutical Preparations

Nexalin Technology, Inc.

NXL · Electromedical & Electrotherapeutic Apparatus

Axogen, Inc.

AXGN · Electromedical & Electrotherapeutic Apparatus

agilon health, inc.

AGL · Services-Misc Health & Allied Services, NEC

: 11/08/2026